NCT03431350 2026-04-13QUESTJanssen Research & Development, LLCPhase 2 Active not recruiting136 enrolled 29 charts
NCT03748641 2026-04-13MAGNITUDEJanssen Research & Development, LLCPhase 3 Active not recruiting765 enrolled 16 charts 2 FDA
NCT05968599 2026-02-25A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate CancerPfizerCompleted2,731 enrolled 14 charts
NCT02204072 2025-07-15BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)Boehringer IngelheimPhase 1 Completed120 enrolled 28 charts
NCT05169684 2025-06-10A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate CancerBristol-Myers SquibbPhase 2 Terminated10 enrolled 15 charts